COGT logo

Cogent Biosciences (COGT) Company Overview

Profile

Full Name:

Cogent Biosciences, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

March 29, 2018

Indexes:

Not included

Description:

Cogent Biosciences focuses on developing innovative therapies for genetic diseases, particularly those caused by mutations in specific genes. The company aims to improve patient outcomes through targeted treatments, using advanced science and technology to address unmet medical needs in rare and serious conditions.

Events Calendar

Earnings

Next earnings date:

Feb 26, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Feb 26, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Nov 9, 2020

Analyst ratings

Recent major analysts updates

Jan 14, 25 HC Wainwright & Co.
Buy
Dec 11, 24 Needham
Hold
Dec 11, 24 HC Wainwright & Co.
Buy
Dec 10, 24 Needham
Buy
Dec 9, 24 Needham
Buy
Nov 14, 24 JP Morgan
Overweight
Nov 13, 24 Needham
Buy
Nov 4, 24 HC Wainwright & Co.
Buy
Oct 24, 24 Needham
Buy
Sep 24, 24 Citigroup
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data
Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data
Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data
COGT
seekingalpha.comJanuary 18, 2025

Bezuclastinib is COGT's main value driver, currently undergoing 3 late-stage trials for SM and GIST. COGT's SUMMIT Part 2 for nonAdvSM will give us decisive data in July 2025, which I consider its main catalyst this year. Bezuclastinib could target an aggregate TAM of up to $2.5 billion across NonAdvSM, AdvSM, and GIST, which dwarves its current market cap.

Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
COGT
globenewswire.comDecember 8, 2024

52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with median duration of response and median PFS not yet reached Top-line data from APEX Part 2 on-track for mid-2025 Cogent to host investor webcast on Monday, December 9 at 8:00 a.m. ET WALTHAM, Mass.

Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting
Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting
Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting
COGT
zacks.comJune 28, 2024

Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.

Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
COGT
globenewswire.comJune 14, 2024

Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions

Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
COGT
globenewswire.comMay 23, 2024

WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations. A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients with systemic mastocytosis (SM) or Gastrointestinal Stromal Tumors (GIST).

3 Lost Formula Stocks to Consider for the 2nd Half of 2023
3 Lost Formula Stocks to Consider for the 2nd Half of 2023
3 Lost Formula Stocks to Consider for the 2nd Half of 2023
COGT
GuruFocusJuly 7, 2023

Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023.

Cogent Biosciences Announces Participation at Upcoming Investor Conferences
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
COGT
GlobeNewsWireApril 12, 2023

WALTHAM, Mass. and BOULDER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the following upcoming virtual investor conferences:

FAQ

  • What is the ticker symbol for Cogent Biosciences?
  • Does Cogent Biosciences pay dividends?
  • What sector is Cogent Biosciences in?
  • What industry is Cogent Biosciences in?
  • What country is Cogent Biosciences based in?
  • When did Cogent Biosciences go public?
  • Is Cogent Biosciences in the S&P 500?
  • Is Cogent Biosciences in the NASDAQ 100?
  • Is Cogent Biosciences in the Dow Jones?
  • When was Cogent Biosciences's last earnings report?
  • When does Cogent Biosciences report earnings?
  • Should I buy Cogent Biosciences stock now?

What is the ticker symbol for Cogent Biosciences?

The ticker symbol for Cogent Biosciences is NASDAQ:COGT

Does Cogent Biosciences pay dividends?

No, Cogent Biosciences does not pay dividends

What sector is Cogent Biosciences in?

Cogent Biosciences is in the Healthcare sector

What industry is Cogent Biosciences in?

Cogent Biosciences is in the Biotechnology industry

What country is Cogent Biosciences based in?

Cogent Biosciences is headquartered in United States

When did Cogent Biosciences go public?

Cogent Biosciences's initial public offering (IPO) was on March 29, 2018

Is Cogent Biosciences in the S&P 500?

No, Cogent Biosciences is not included in the S&P 500 index

Is Cogent Biosciences in the NASDAQ 100?

No, Cogent Biosciences is not included in the NASDAQ 100 index

Is Cogent Biosciences in the Dow Jones?

No, Cogent Biosciences is not included in the Dow Jones index

When was Cogent Biosciences's last earnings report?

Cogent Biosciences's most recent earnings report was on Nov 12, 2024

When does Cogent Biosciences report earnings?

The next expected earnings date for Cogent Biosciences is Feb 26, 2025

Should I buy Cogent Biosciences stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions